New Method Quantifies Immunostimulatory Drug GMDP in Human Blood for PK Studies
Determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using HPLC-MS/MS and its application to a pharmacokinetic study.
Background
Glucosoaminyl-muramyl-dipeptide (GMDP) is an immunostimulatory drug recognized for its potential to modulate the immune system and enhance host defense mechanisms. For any drug, accurate measurement of its concentration in the body is paramount for understanding its pharmacokinetics (how the body affects the drug), optimizing dosing strategies, and ensuring patient safety and efficacy. Previously, there was no fully validated, sensitive, and specific analytical method available to precisely quantify GMDP concentrations in human plasma, which is a critical prerequisite for conducting comprehensive pharmacokinetic studies.